



Press Release

## Poxel Announces its 2017 Financial Calendar

**Lyon, France, December 20, 2016** – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announces its schedule for the publication of financial information for 2017.

Event	Date*
2016 Q4 Financial Update	January 27, 2017
2016 Full Year Financial Statement	April 3, 2017
2017 Q1 Financial Update	May 4, 2017
2017 Q2 Financial Update	July 10, 2017
2017 First Half Financial Statement	September 21, 2017
2017 Q3 Financial Update	October 16, 2017
2017 Q4 Financial Update	January 22, 2018

*\*Subject to modification.*

### About Poxel

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxel.com](http://www.poxel.com))

### Contacts

#### Poxel SA

Jonae R. Barnes  
Senior Vice President, Investor Relations and Public Relations  
[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)  
+1 617 818 2985

#### Investor relations / Media - EU/US

MacDougall Biomedical Communications  
Gretchen Schweitzer or Stephanie May  
[smay@macbiocom.com](mailto:smay@macbiocom.com)  
+ 49 89 2424 3494 or + 49 175 571 1562

#### Investor relations / Media - France

NewCap  
Florent Alba/Nicolas Mérieau  
[poxel@newcap.fr](mailto:poxel@newcap.fr)  
+ 33 1 44 71 98 55